Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Immix Biopharma, Inc.NASDAQ: IMMX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $10.68M rose 128.0% year over year, ahead of the +65.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at +48.4% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +128.0% holds above the trailing-twelve-month pace of +65.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 26.85M USD
- Year-over-year change
- +18.4%
- 4-year CAGR
- +111.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.85M | +18.4% |
| FY2024 | 2024-12-31 | 22.67M | +40.5% |
| FY2023 | 2023-12-31 | 16.14M | +96.4% |
| FY2022 | 2022-12-31 | 8.22M | +507.9% |
| FY2021 | 2021-12-31 | 1.35M | — |
Operating Expenses vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +65.2% is the 3rd highest of 11, against a peer median of +4.0%.
- Over three fiscal years its annual growth of +48.4% compares with a peer median of +11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $596M USD | -0.7% | +16.7% | 509.4% | |
| LTM Sep 2026 | $333.75M USD | +278.1% | +101.5% | 297994.6% | |
| LTM Aug 2026 | $317.52M USD | +142.5% | +109.8% | 45.2% | |
| FY2025 | €246.06M EUR | +42.2% | +159.6% | — | |
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $109.61M USD | +8.6% | -4.8% | — | |
| LTM Mar 2026 | $99.95M USD | -10.4% | -13.9% | 281.2% | |
| FY2025 | A$70.06M AUD | +39.0% | +29.1% | 1388.9% | |
| LTM Mar 2026 | $36.37M USD | -15.3% | +7.1% | 6928.2% | |
| LTM Mar 2026 | $35.95M USD | +65.2% | +48.4% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥34.74M CNY | -93.5% | -66.4% | — |
| Peer median (excluding IMMX) | — | +4.0% | +11.9% | 509.4% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 364.5K |
| Gross Profit | 0 | 0 | 0 | 0 | (364.5K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.53K | 4.2M | 8.74M | 11.29M | 16.26M |
| Selling, General & Admin | 1.23M | 4.02M | 7.41M | 11.38M | 13.7M |
| Operating Expenses | 1.35M | 8.22M | 16.14M | 22.67M | 26.85M |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| EBITDA | (24.2M) | (8.22M) | (15.56M) | (21.54M) | (29.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.35M) | (8.22M) | (16.14M) | (22.67M) | (27.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 572.01K | 1.02M | 555.53K |
| Interest Expense | 179.85K | 497 | 0 | 0 | 0 |
| Other Income / Expenses | (23.03M) | (497) | 572.01K | 1.02M | (2.19M) |
| Income Before Tax | (24.38M) | (8.22M) | (15.57M) | (21.66M) | (29.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 6.01K | 10.27K | 26.42K | 41.04K | 37.72K |
| Net Income | (24.38M) | (8.23M) | (15.43M) | (21.61M) | (29.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| EPS (Diluted) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| Weighted Avg Shares | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
| Weighted Avg Shares (Diluted) | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.